Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

(2018) Masao Hashimoto et al.   Annual Review of Medicine

Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response

(2018) Xuanwei Zhang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of PD-1 during effector CD8 T cell differentiation

(2018) Eunseon Ahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8 + Tumor-Infiltrating Lymphocytes Identified Patients With Poor Prognosis in Rectal Cancer: A Matched Comparison Analysis

(2017) Yu Jin Lim et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy

(2017) Andrew Bang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

(2017) Paolo A Ascierto et al.   LANCET ONCOLOGY

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

(2017) Narek Shaverdian et al.   LANCET ONCOLOGY

cGAS is essential for the antitumor effect of immune checkpoint blockade

(2017) Hua Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

(2017) Claire Vanpouille-Box et al.   Nature Communications

Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors

(2017) Benjamin Frey et al.   Frontiers in Immunology

TREX1 dictates the immune fate of irradiated cancer cells

(2017) Claire Vanpouille-Box et al.   OncoImmunology

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation

(2017) Megan Morisada et al.   OncoImmunology

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

(2016) Jack M. Qian et al.   CANCER

Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing  -Irradiation

(2016) M. Hettich et al.   CANCER RESEARCH

Key Role of DAMP in Inflammation, Cancer, and Tissue Repair

(2016) Franco Pandolfi et al.   CLINICAL THERAPEUTICS

Systematic review of case reports on the abscopal effect

(2016) Yazan Abuodeh et al.   CURRENT PROBLEMS IN CANCER

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab

(2016) Rosie Qin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

(2016) Anja Derer et al.   Frontiers in Immunology

Current clinical trials testing the combination of immunotherapy with radiotherapy

(2016) Josephine Kang et al.   Journal for ImmunoTherapy of Cancer

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy

(2016) Kristina H. Young et al.   PLoS One

Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment

(2015) Ana P. Kiess et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial

(2015) Encouse B Golden et al.   LANCET ONCOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

(2015) Sofia R. Gameiro et al.   Oncotarget

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells

(2014) Lorenz Kulzer et al.   Journal of Immunotoxicology

In VivoEffects of Lattice Radiation Therapy on Local and Distant Lung Cancer: Potential Role of Immunomodulation

(2014) Saravana Kanagavelu et al.   RADIATION RESEARCH

TGF  Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models

(2014) K. H. Young et al.   Cancer Immunology Research

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Radiation and immunotherapy: a synergistic combination

(2013) Anusha Kalbasi et al.   JOURNAL OF CLINICAL INVESTIGATION

Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer

(2013) Shankar Siva et al.   Journal of Thoracic Oncology

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS)

(2012) Heon Joo Park et al.   RADIATION RESEARCH

Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2--Tumor and Immunological Responses

(2012) S. K. Seung et al.   Science Translational Medicine

Role of Lymphocytic Choriomeningitis Virus (LCMV) in Understanding Viral Immunology: Past, Present and Future

(2012) Xin Zhou et al.   Viruses-Basel

The convergence of radiation and immunogenic cell death signaling pathways

(2012) Encouse B. Golden et al.   Frontiers in Oncology

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity

(2011) B. C. Burnette et al.   CANCER RESEARCH

Maximizing Tumor Immunity With Fractionated Radiation

(2011) Dörthe Schaue et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE

A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status

(2008) Jerry R. Williams et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY